Carlsmed outlines $74M-$78M 2026 revenue outlook as CMS finalizes new aprevo lumbar MS-DRGs effective October 1 (NASDAQ:CARL)
· seekingalpha.com
Carlsmed (CARL) Q2 2026 earnings call recap: 57% revenue growth, raised FY26 guidance, CMS IPPS DRG changes, and Q4 launches—read key takeaways.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...